In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.

Irene Galani Maria SouliD KatsalaIlias Karaiskos Helen Giamarellou Anastasia Antoniadou

Published in: The Journal of antimicrobial chemotherapy (2024)

Apramycin combinations may have potential as a treatment option for XDR/pandrug-resistant (PDR) A. baumannii infections and warrant validation in the clinical setting, when this new aminoglycoside is available for clinical use.

Keyphrases

acinetobacter baumannii
drug resistant
multidrug resistant
pseudomonas aeruginosa
gram negative
escherichia coli
klebsiella pneumoniae
climate change
human health